Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). (Q46641045)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 August 2017

Language	Label	Description	Also known as
English	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).	scientific article published on 21 August 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). (English)

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

1 reference

based on heuristic

inferred from title

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

Claudia Trenkwalder

6

object named as

Claudia Trenkwalder

0 references

Wolfgang H. Oertel

1

object named as

Wolfgang Oertel

1 reference

Europe PubMed Central

22 February 2018

PMC publication ID

Robert A Hauser

5

object named as

Robert A Hauser

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

3

object named as

Rajesh Pahwa

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

Caroline M Tanner

4

object named as

Caroline M Tanner

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

Karla M. Eggert

2

object named as

Karla Eggert

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

author name string

Reinhard Ehret

7

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

Jean Philippe Azulay

8

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

Stuart Isaacson

9

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

Larissa Felt

10

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

Mary Jean Stempien

11

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

language of work or name

0 references

publication date

21 August 2017

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

Movement Disorders

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

32

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

12

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

1701-1709

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Falls in ambulatory non-demented patients with Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Which dyskinesia scale best detects treatment response?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Amantadine: the journey from fighting flu to treating Parkinson disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Amantadine for dyskinesia in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Dopamine: Release from the Brain in vivo by Amantadine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

24 May 2018

Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

15 August 2018

Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

15 August 2018

Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

15 August 2018

The clinically important difference on the unified Parkinson's disease rating scale.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5763269

15 August 2018

Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28833562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amantadine in the Treatment of Parkinson's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28833562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28833562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia

1 reference

https://pubmed.ncbi.nlm.nih.gov/28833562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28833562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amantadine dosage in treatment of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28833562

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/MDS.27131

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 February 2018

http://europepmc.org/abstract/PMC/5763269

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46641045&oldid=1796446644"